Semantic Scholar uses AI to extract papers important to this topic.
BackgroundThe resistance to PD-1/PD-L1 inhibitors for the treatment of melanoma have prompted investigators to implement novel… Expand Heterogeneity of BRAF mutation in melanoma has been a controversial subject. Quantitative data on BRAF allele frequency (AF) are… Expand Studies on melanoma brain metastases (MBM) with regard to mutational status are lacking. We investigated the outcomes of MBM in… Expand 9541Background: BRAF V600E and V600K/R mm have distinct clinicopathologic features suggesting different etiology. V600K/R mm… Expand Die Einführung der BRAF-Inhibitoren hat die Therapiemöglichkeiten beim nicht resezierbaren beziehungsweise metastasierten… Expand In the past few years, the treatment of melanoma has been revolutionised by the approval of the CTLA-4 antibody, ipilimumab, and… Expand BackgroundThe approval of vemurafenib in the US 2011 and in Europe 2012 improved the therapy of not resectable or metastatic… Expand CONTEXT
A polymerase chain reaction-based companion diagnostic (cobas 4800 BRAF V600 Mutation Test) was recently approved by the… Expand The presence of a BRAF mutation in a melanoma tumor predicts response to BRAF inhibitors; however, the biological characteristics… Expand Activating mutations in BRAF kinase are common in melanomas. Clinical trials with PLX4032, the mutant-BRAF inhibitor, show… Expand